Georgia Ozempic Vision Loss Lawyer: NAION Blindness Claims

This page is for Georgians who were taking Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 drug, lost part or all of the vision in one eye, and were told by an eye doctor it was NAION (nonarteritic anterior ischemic optic neuropathy). It’s also for family members doing the reading for them. We’re Fob & Foster Personal Injury Lawyers, a Birmingham firm, and attorney James Z. Foster is licensed in Georgia.

Below: what the science shows and doesn’t, where the federal case stands, Georgia’s deadline, and which records to gather this week. If you searched for an Ozempic lawyer near me from Atlanta, Savannah or Valdosta, the process is the same anywhere in Georgia: phone or video calls with us, and your records doing most of the talking.

What NAION Is: Lost Blood Flow to the Front of the Optic Nerve

The optic nerve carries what your eye sees to your brain. Where it enters the back of the eye (the optic disc), it’s fed by very small blood vessels. NAION happens when blood flow to that segment drops and the nerve tissue is starved of oxygen. Eye doctors call it a stroke of the optic nerve, and the nerve fibers lost don’t grow back.

Many people notice it on waking: part of the vision in one eye is dim, blurry or gone, often the upper or lower half. There’s usually no pain. The loss is frequently permanent, though some eyes improve a little over the following months. Someone who has had NAION in one eye also faces a risk that the other eye is affected later, which is part of why these claims carry real damages.

Why the Exact Diagnosis Matters for a Claim

Sudden vision loss has several causes, and a claim depends on the diagnosis actually being NAION. The look-alike that matters most is arteritic ischemic optic neuropathy from giant cell arteritis, a blood-vessel inflammation treated as an emergency because it can take the second eye. Doctors rule it out with blood tests (sedimentation rate and C-reactive protein) and questions about headache, scalp tenderness and jaw pain.

The first thing we look for in a file is an ophthalmology or neuro-ophthalmology note that says NAION in so many words and explains how other causes were excluded. Georgia patients get that workup from neuro-ophthalmologists in Atlanta or Augusta or from eye practices in Columbus, Macon or Albany. Either works if the testing is documented.

Warning Signs That Should Send You to an Eye Doctor the Same Day

No treatment has been proven to restore vision lost to NAION, but a same-day exam still matters. It rules out giant cell arteritis and creates the record a claim stands on. Get seen right away for:

• Sudden blurring, dimming or a dark shadow over part of the vision in one eye.
• Loss of the top or bottom half of what you see out of one eye.
• Colors that look washed out in one eye compared with the other.
• New vision loss along with headache, scalp tenderness or jaw pain when chewing. Tell the doctor about those symptoms immediately.

Do not stop or change Ozempic, Wegovy, Mounjaro or any other prescription on your own. Tell the prescriber about the eye diagnosis and decide together. That medical call belongs to you and your doctor, not a law firm.

Does Ozempic Cause Blindness? What the Published Studies Report

This question isn’t settled. It’s the exact question the federal judge has put first. What exists today is a group of observational studies reporting more NAION among people taking semaglutide (the ingredient in Ozempic, Wegovy and Rybelsus) or other GLP-1 drugs than among comparison groups.

A hazard ratio of 4.28 means roughly four times the rate, not four in ten people losing vision. Europe’s drug regulator classifies NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and the veterans figures show a difference of about ten cases per 10,000 people over three years.

The companies will argue confounding: people on these drugs often have diabetes, high blood pressure or sleep apnea, each tied to NAION on its own. Plaintiffs’ experts will point to consistent findings across countries, comparisons against other diabetes drugs, and regulators abroad acting on the evidence. Plaintiffs’ expert reports are due March 26, 2027, and Rule 702 challenges to those experts are due July 2, 2027. That’s when the science gets tested.

How Regulators Abroad and the FDA Have Handled the NAION Signal

That gap is the center of a Georgia failure-to-warn claim. Under the learned intermediary doctrine, the duty to warn runs to the prescribing doctor, so the case asks what Novo Nordisk and Eli Lilly told American doctors about vision risk, and when. An endocrinologist in Marietta writing a prescription in 2025 had no NAION warning on the U.S. label to pass along.

The companies will say the FDA saw the same signal and didn’t require a warning. But under Wyeth v. Levine (U.S. Supreme Court, 2009), a brand-name manufacturer is responsible for its own label and can strengthen a warning through FDA’s “changes being effected” process. Whether these companies should have is part of the MDL’s warning-adequacy phase.

Ozempic, Wegovy, Mounjaro and Zepbound: Does the Brand Matter?

It does. The brand decides who you sue, how deep the evidence runs, and whether the product can be traced at all.

Defendant. Semaglutide and liraglutide products are Novo Nordisk’s; Trulicity, Mounjaro and Zepbound are Lilly’s. If you switched brands when an insurer changed coverage, both companies may be involved, and your pharmacy history has to show which drug you were on before your vision changed.

Evidence. Most published NAION research, including the Harvard study and the European conclusion, concerns semaglutide. Australia’s update covered the whole class, but its expert advisers found the evidence may support the signal for semaglutide, not for dulaglutide or tirzepatide. Trulicity, Mounjaro and Zepbound claims lean harder on class-wide arguments, and we’ll say so up front.

Compounded semaglutide. Med-spa and online-clinic product wasn’t made by Novo Nordisk, which creates a product-identification problem. Call anyway; we’ll look at what you received.

Where the Federal Ozempic Vision Loss MDL Stands

On December 15, 2025, the Judicial Panel on Multidistrict Litigation created MDL 3163 in the Eastern District of Pennsylvania in Philadelphia, before Judge Karen S. Marston, with Novo Nordisk and Eli Lilly as defendants. An MDL gathers similar federal cases before one judge for discovery and pretrial rulings, but every case stays an individual lawsuit with its own records and damages.

How the Case Count Has Grown in 2026

The October figure is from the JPML’s pending-dockets report.

The Court’s Schedule Through Mid-2027

Case Management Order 12 (July 2, 2026) put general causation and preemption/warning adequacy first. Case Management Order 14 (August 27, 2026) scheduled these dates:

So there will be no NAION trial in this MDL in 2026, and the causation fight will be fully briefed by August 31, 2027. If plaintiffs clear that stage, the court has said bellwether selection can follow quickly; if they don’t, many federal cases could face dismissal.

Why a Georgia Case Goes to Philadelphia, and You Usually Don’t

A Georgia federal NAION case becomes part of MDL 3163, where court-appointed leadership and co-counsel carry pretrial work. Your part is typically records, a fact sheet and calls with us. Depositions, if your case is picked for workup, are generally arranged near home, and a case that’s tried generally goes back to the district where it was filed unless the parties agree otherwise.

The New Jersey State Court Track

New Jersey has a separate multicounty litigation for NAION claims before Judge Gregg A. Padovano in Bergen County. Novo Nordisk’s U.S. headquarters is in New Jersey, which is why that court can be an option for some claims. We decide forum with co-counsel one case at a time.

The Separate Stomach-Injury MDL

Ozempic headlines about gastroparesis, ileus and intestinal obstruction concern MDL 3094, before the same judge, with 4,025 cases pending as of October 1, 2026. If you had both a GI injury and NAION, tell us about both.

Who May Have an Ozempic Vision Loss Claim in Georgia

When we screen a Georgia NAION case, we look for:

• You took Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro or Zepbound, and a pharmacy or insurance record proves it.
• An ophthalmologist or neuro-ophthalmologist diagnosed NAION (charts sometimes say “ischemic optic neuropathy” or “AION”).
• The vision loss began while you were on the drug or shortly after you stopped.
• Testing documented the loss: a dilated exam, visual fields, OCT imaging.
• Giant cell arteritis and other causes were ruled out.
• You live in Georgia or were treated here, and the claim is inside Georgia’s deadline.

These usually don’t support a claim: blurry vision that cleared as blood sugar settled (common early in diabetes treatment, and not NAION), diabetic retinopathy, cataracts, and vision problems that predate the first GLP-1 prescription. With the patient’s permission, we’re glad to work with a family member who is helping.

Does My Diabetes or Sleep Apnea Hurt My Case?

It complicates the case, and you should hear that from your own lawyer first. NAION has well-known risk factors unrelated to any drug: diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, age over 50, and a small, crowded optic disc that eye doctors call a “disc at risk.” Many people on Ozempic or Mounjaro have two or three of these, and the companies will say your NAION came from your health history.

How Those Arguments Get Answered

• Comparison groups shared the conditions. The Danish-Norwegian and veterans studies compared GLP-1 drugs with SGLT2 inhibitors, another diabetes drug class, so diabetes sat on both sides.
• Timing carries weight. Vision loss within weeks or months of starting the drug or raising the dose is hard to pin on a condition you’d had for years without an eye problem.
• Risk factors appear in nearly every case. Experts weigh your full history, and a risk factor alone doesn’t end a claim.
• Treatment records help. Diagnosed, treated sleep apnea with CPAP data reads differently than apnea nobody knew about, and so do well-controlled A1C and blood pressure numbers.

Georgia’s comparative fault statute, O.C.G.A. § 51-12-33, reduces or bars recovery based on a person’s share of fault. Having diabetes isn’t fault. Fault arguments are about conduct, such as ignoring an instruction to report vision changes, and we deal with them in your file, not in the abstract.

Records That Prove a NAION Claim

Request these now, and ask for test printouts and images, not just visit summaries.

Two things people skip: keep any pens, cartons or pharmacy labels (they show brand and lot), and write a dated one-page account of the morning you noticed the vision loss and how your work and driving have changed since.

How Georgia’s Two-Year Deadline and Ten-Year Repose Apply to NAION

Georgia generally gives an injured person two years to file a personal injury lawsuit, O.C.G.A. § 9-3-33, and the clock usually starts when the injury happens. Georgia’s discovery rule, which can delay the start until you knew or should have known of the injury and its cause, is generally limited to injuries that develop over an extended period. NAION usually strikes suddenly, and most people can name the morning it happened, so the safest assumption is that your two years started then.

Why the Start Date Gets Fought Over

Some people argue their clock shouldn’t start until they could have linked the vision loss to the drug. Georgia courts apply that rule narrowly, and even where it’s argued, the defense will point to July 2024, when the Harvard study was widely reported, and to the MDL’s creation in December 2025. If your vision loss happened before late October 2024, your deadline may already have passed; if it happened in late 2024 or 2025, it may be close. Don’t calculate it from an article; call us and we’ll go through your dates.

The Ten-Year Statute of Repose and the Disease Exception

A strict liability claim generally must be brought within ten years of the first sale for use or consumption of the product that caused the injury, O.C.G.A. § 51-1-11(b)(2). With monthly refills, the product at issue is usually recent, so repose rarely blocks a GLP-1 claim. Under § 51-1-11(c), the ten-year bar also doesn’t apply to negligence claims over products that cause a disease or birth defect, or to willful, reckless or wanton conduct, and a manufacturer keeps a duty to warn once it learns of a danger. Whether NAION counts as a “disease” there is an open argument. In most Ozempic cases, the two-year period is the deadline that bites.

Georgia Product Liability Law Behind an Ozempic Claim

Strict Liability, Negligence and the Learned Intermediary Rule

Georgia imposes strict liability on manufacturers for defective products, O.C.G.A. § 51-1-11(b)(1). For prescription drugs, the alleged defect here is the warning: plaintiffs say U.S. labels didn’t disclose a NAION risk the companies knew or should have known about. Negligence claims run alongside, focused on what the companies studied and what they did with the safety signals they saw.

Because Georgia warnings run to the prescriber, your doctor’s knowledge matters: would they have prescribed differently, or told you to report vision changes at once, if the U.S. label had carried a NAION warning? Your doctor doesn’t have to take sides. We need the facts of what they knew.

Damages, Punitive Awards and Wrongful Death

Georgia doesn’t cap compensatory damages. Much of the harm in a vision case is noneconomic: lost depth perception, no more night driving, fear for the other eye. Eye care, low-vision aids, lost income and help at home are recoverable too. In product liability cases, punitive damages aren’t limited by the general $250,000 cap, but O.C.G.A. § 51-12-5.1(e) sends 75% of any punitive award, less a share of costs and fees, to the state treasury. NAION isn’t fatal, but if a family member died from another GLP-1 injury, O.C.G.A. § 51-4-2 lets the family recover the full value of the life, generally within two years.

What Affects the Value of an Ozempic Vision Loss Case

There are no NAION verdicts in this litigation to point to, and anyone quoting an average payout is guessing. These facts tend to make a case stronger or weaker:

• How much vision was lost on visual field and acuity testing, and whether any came back.
• Whether the second eye has been affected.
• Age and work, such as a commercial driver who can no longer pass a vision screening.
• The gap between starting or increasing the drug and the vision loss.
• How solid the diagnosis is, and how well other causes were excluded.
• Risk factors and how well they were controlled.
• Which drug, since semaglutide claims rest on the deepest research.
• How the 2027 causation and Rule 702 rulings come out, which affects every case.

What to Do This Week If You Lost Vision on a GLP-1 Drug

1. Keep every eye appointment, and ask the doctor to state the diagnosis and onset date clearly in the chart.
2. Talk to your prescriber before changing any medication.
3. Request your eye records, including visual field printouts and OCT reports.
4. Print a pharmacy fill history back to your first GLP-1 prescription.
5. Save pens, cartons and labels, and screenshot portal messages about your vision.
6. Stay off social media about your eyes and the drug. The companies’ lawyers read it.
7. Call us at (205) 407-6009 before you sign with anyone and before your deadline gets close.

Ozempic Vision Loss Litigation Updates

October 20, 2026 – Master Complaint Due Next Week; Docket at 247 Cases

The JPML’s October 1 report listed 247 pending actions in MDL 3163, up 31 from September. The Master Complaint is due October 28, 2026, with status conferences scheduled for November 17 and December 15.

August 27, 2026 – CMO 14 Sets the Discovery and Expert Schedule

Fact discovery closes December 18, 2026 (Lilly) and February 26, 2027 (Novo Nordisk); expert and Rule 702 deadlines follow in 2027.

July 2, 2026 – CMO 12 Puts General Causation and Warning Adequacy First

Bellwether selection was deferred. Australia’s TGA added GLP-1 class warnings the same month.

June 2, 2026 – Science Day in Philadelphia

Both sides presented the medicine of NAION and the GLP-1 drugs to Judge Marston.

December 15, 2025 – JPML Creates MDL 3163

Federal NAION cases naming Ozempic, Wegovy, Saxenda and Trulicity were centralized in Philadelphia before Judge Karen S. Marston.

Talk to a Georgia Ozempic Lawyer Today

Fob & Foster Personal Injury Lawyers is based in Birmingham, Alabama, at 2226 1st Ave S, Suite 105, Birmingham, AL 35233. Attorney James Z. Foster is licensed in Georgia, and we review Ozempic vision-loss claims from Atlanta, Marietta, Alpharetta, Athens, Augusta, Macon, Columbus, Savannah, Albany and Valdosta by phone or video. We work alongside national co-counsel.

A free review is one conversation about the drug, your vision, and the health history the defense will raise. Then we’ll tell you straight whether you have a claim and how your Georgia deadline looks. No fee unless we recover.

Call (205) 407-6009 or toll-free (866) 837-1010, or send us your question online.

Related Practice Areas

• Ozempic Vision Loss Lawsuit in Alabama
• Ozempic Vision Loss Lawsuit in Tennessee
• Dupixent Lawsuit in Georgia
• Paragard Lawsuit in Georgia
• Defective Product Claims